A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:
- 11/12/2024 – Illumina had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an “overweight” rating on the stock.
- 11/12/2024 – Illumina had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $156.00 price target on the stock.
- 11/11/2024 – Illumina had its price target lowered by analysts at Piper Sandler from $195.00 to $185.00. They now have an “overweight” rating on the stock.
- 11/6/2024 – Illumina had its price target raised by analysts at Robert W. Baird from $124.00 to $139.00. They now have a “neutral” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at Royal Bank of Canada from $252.00 to $254.00. They now have an “outperform” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at UBS Group AG from $133.00 to $145.00. They now have a “neutral” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at JPMorgan Chase & Co. from $125.00 to $140.00. They now have a “neutral” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at Canaccord Genuity Group Inc. from $130.00 to $145.00. They now have a “hold” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at Barclays PLC from $135.00 to $145.00. They now have an “equal weight” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at TD Cowen from $166.00 to $177.00. They now have a “buy” rating on the stock.
- 11/5/2024 – Illumina had its price target raised by analysts at Citigroup Inc. from $155.00 to $190.00. They now have a “buy” rating on the stock.
- 10/17/2024 – Illumina was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating. They now have a $180.00 price target on the stock.
- 10/17/2024 – Illumina had its price target raised by analysts at Leerink Partners from $160.00 to $200.00. They now have an “outperform” rating on the stock.
- 10/17/2024 – Illumina was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $180.00 price target on the stock.
- 10/15/2024 – Illumina had its price target raised by analysts at Barclays PLC from $125.00 to $135.00. They now have an “equal weight” rating on the stock.
- 10/10/2024 – Illumina had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $252.00 price target on the stock.
Illumina Price Performance
Shares of ILMN traded down $1.45 during mid-day trading on Wednesday, reaching $146.17. 1,769,771 shares of the stock traded hands, compared to its average volume of 2,006,273. The firm has a fifty day moving average price of $138.84 and a 200 day moving average price of $123.95. The company has a market cap of $23.18 billion, a price-to-earnings ratio of -14.68 and a beta of 1.13. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 1 year low of $92.69 and a 1 year high of $156.66.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.
Institutional Trading of Illumina
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
- Five stocks we like better than Illumina
- Trading Stocks: RSI and Why it’s Useful
- Rocket Lab is the Right Stock for the Right Time
- What is the S&P/TSX Index?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.